ClinicalTrials.gg
RecruitingNCT07474727Updated Aug 27, 2026

A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer

A Phase 2 interventional study of AMT-676 and 5-FU in Colorectal Cancer, sponsored by Multitude Therapeutics Inc.. Recruiting at 19 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-27.

Sponsored by Multitude Therapeutics Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,136 studies in Colorectal Neoplasms with a site in China — 526 open to participants now, 604 under way, 67 of them phase 3. Colorectal Neoplasms · China.

Planned enrollment
270th of 891
180 · median 80
Started
2026
with 114 others
Phase 2
349 of 1,136
177 open now
Primary completion
2027-09
later than 409 of 603 live
Registered
1,026th of 1,136
by date

Among the 1,136 studies in Colorectal Neoplasms with a site in China, this one is the 270th largest by planned enrollment of the 891 interventional ones that give a count, is one of 115 that started in 2026, is one of 349 in phase 2, reaches primary completion later than 409 of the 603 other live ones, and was the 1,026th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

526 of the 1,136 studies in Colorectal Neoplasms with a site in China are open now. Recruiting first, the newest first:

521 more — sign in →

All 526 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,136 studies in Colorectal Neoplasms with a site in China, or all of them as a file.
02

Study summary

This study is an open, multi-center, phase II study, aiming to evaluate the safety, tolerability and efficacy of AMT-676 combined with 5-fluorouracil, leucovorin, bevacizumab (or cetuximab) in participants with advanced colorectal cancer, and to assess the PK(Pharmacokinetic) characteristics and immunogenicity of AMT-676.

03

Conditions studied

  • Colorectal Cancer
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must be willing and able to sign the ICF, and to adhere to the study visit schedule and other protocol requirements
  • Patients with confirmed, unresectable advanced colorectal adenocarcinoma
  • Patients must have at least one as per version 1.1
  • (ECOG) performance status of 0-1
  • ≥6 months
  • Patients must have adequate organ function
  • Male and female individuals with child bearing potential must agree to take effective measures from the moment they sign the form until 6 months after the last administration of the study drug
  • WCBP(Women of ) must have a negative serum pregnancy test within 7 days prior to first dose of the IMP
  • Male patients must agree not to donate sperm, and female patients must agree not to donate eggs, while on study treatment and for at least 3 months and 6 months, respectively, after the last dose of the IMP( Medicinal Product)
  • Availability of tumor tissue sample

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with any same target
  • Systemic anti-neoplastic therapy within five half-lives or 21 days, whichever is shorter, prior to first dose of the IMP
  • Persistent toxicities from previous systemic anti-neoplastic treatments of Grade >1
  • Major surgery within 28 days prior to first dose of the IMP, or no recovery from side effects of such intervention, or a surgery is planned to be conducted within the expected participation period of the trial or within 4 weeks after the last administration of the drug
  • History of thromboembolic or cerebrovascular events during last 6 mouths
  • During the three months prior to the first administration of the drug, there were any life-threatening bleeding events, or grade 3 or higher gastrointestinal/venous variceal bleeding events that required blood transfusion, endoscopy, or surgical treatment. Or there were other diseases that the researchers believed posed a higher risk of bleeding or thrombosis during the study period
  • Has a history of interstitial lung disease (ILD)/pneumonitis that required , or current ILD/pneumonitis, or suspected ILD/pneumonitis , or other lung disease significantly impacting lung function at baseline.
  • Any other concurrent diseases or conditions that could affect the research judgment or impede the completion of the research procedures and follow-up checks
  • Central nervous system (CNS)
  • Have a history of active or acute diverticulitis, abdominal abscess, gastrointestinal obstruction, fistula, or peritoneal cancer
  • Any evidence indicates severe or uncontrolled systemic diseases
  • Acute and/or bacterial, fungal or viral infection including (HBV), (HCV), known (HIV).
  • Administration of a within 28 days prior to the administration of the first dose of the IMP
  • Patients requiring concurrent treatment of strong/moderate inhibitors or strong inducers of cytochrome P450 3A4 or 1A2 enzyme ( or CYP1A2) within 2 weeks prior to the first dose and during the study treatment
  • Known or suspected severe allergy/ (resulting in treatment discontinuation) to monoclonal antibodies
  • Known or suspected intolerance to the components of the IMP
  • Concurrent participation in another therapeutic clinical trial
  • Pregnant or breast-feeding females
  • Investigator determined that the trial participants who were not suitable to participate in this study for other reasons
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    AMT-676(dose level 1)+5-FU+Leucovorin+Bevacizumab or Cetuximab(if applicable)

    Drug: AMT-676 · Drug: 5-FU · Drug: Leucovorin · Drug: Bevacizumab · Drug: Cetuximab

  • Experimental
    AMT-676(dose level 2)+5-FU+Leucovorin+Bevacizumab or Cetuximab(if applicable)

    Drug: AMT-676 · Drug: 5-FU · Drug: Leucovorin · Drug: Bevacizumab · Drug: Cetuximab

  • Experimental
    oxaliplatin/irinotecan+5-FU+ leucovorin +bevacizumab (or cetuximab)

    Drug: 5-FU · Drug: Leucovorin · Drug: Bevacizumab · Drug: Cetuximab · Drug: Irinotecan · Drug: Oxaliplatin

  • Experimental
    AMT-676+5-FU+Leucovorin+Bevacizumab or Cetuximab(if applicable)+Oxaliplatin

    Drug: AMT-676 · Drug: 5-FU · Drug: Leucovorin · Drug: Bevacizumab · Drug: Cetuximab · Drug: Oxaliplatin

Interventions

  • DrugAMT-676

    Patients will get different dose levels treatment of AMT-676. AMT-676 will be Administered as an intravenous (IV) infusion every 2 weeks (Q2W) .

  • Drug5-FU

    5-FU 400 mg/m\^2 IV bolus on day 1, followed by 1200 mg/m\^2/day x 2 days (total 2400 mg/m\^2 over 46-48 hours) IV continuous infusion, q2w

  • Leucovorin 400 mg/m\^2 IV day 1, q2w

  • Bevacizumab 5 mg/kg IV, day 1

  • Cetuximab 500 mg/m\^2 IV over 2 hours, day 1, q2w

  • Irinotecan 180 mg/m\^2 IV, day 1

  • Oxaliplatin 85 mg/m\^2 IV, day 1

06

What researchers measure

Primary outcomes

  1. AE & SAE

    Type, incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0

    Time frame: 30 days after the last treatment

  2. MTD

    Maximum Tolerated Dose will be determined by DLTs

    Time frame: 28 days after first dose

  3. DLTs

    Incidence of dose limiting toxicities

    Time frame: 28 days after first dose

  4. ORR

    Overall response rate

    Time frame: through study completion, an average of 18 months

  5. PFS

    Progression-free survival

    Time frame: through study completion, an average of 18 months

Secondary outcomes

  1. Cmax

    maximum concentration of the ADC, total antibody and free payload

    Time frame: From first dose to end of treatment, an average of 1 year

  2. Ctrough

    predose concentration of the ADC, total antibody and free payload

    Time frame: From first dose to end of treatment, an average of 1 year

  3. AUC

    Area Under the Curve of the ADC, total antibody and free payload

    Time frame: From first dose to end of treatment, an average of 1 year

  4. Specification of anti-drug antibodies

    Time frame: From first dose to end of treatment, an average of 1 year

  5. Quantification of anti-drug antibodies

    Time frame: From first dose to end of treatment, an average of 1 year

07

Study locations

8 of 19 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Sep 2027, 17 months after the start.

Of 120 industry-sponsored phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 72. This study's planned 17 months is below that.

Counting every sponsor, half of 618 studies reached it within 49 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2026
First posted
Mar 16, 2026
StartActual
Apr 29, 2026
Primary completionEst.
Sep 30, 2027
CompletionEst.
Feb 28, 2028
Last update
Aug 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07474727
Lead sponsor
Multitude Therapeutics Inc.
Responsible party
Sponsor
First posted
Mar 16, 2026
Start date
Apr 29, 2026
Primary completion
Sep 30, 2027 (estimated)
Completion
Feb 28, 2028 (estimated)
Last update
Aug 27, 2026

Study contacts

Minqi Guan
Contact
minqi.guan@multitudetherapeutics.com
15895820062

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion